
Sign in to rate this tool.
Overview

Ibex AI Com offers AI‑powered diagnostic tools that help pathologists identify and classify cancer in tissue slides. The company markets its solutions as “clinical‑grade” and says they have been deployed worldwide, appearing in the system of choice for several leading health systems.
The platform centers on two main algorithms, Ibex Breast and Ibex Prostate. Each model was created by teams of pathologists who collected and labeled more than 10 million slides from several pathology institutions. The trained deep‑learning networks ingest whole‑slide image files, typically in SVS or NDPI format, and scan them at 40× magnification. Output includes heat‑map overlays that highlight regions of suspected malignancy, a probability score for cancer presence, and ancillary metrics such as nuclear grade, in‑situ carcinoma grading, or tumor area fraction. Pathologists can review these predictions on a slide viewer, comparing the AI‐generated annotations with their own inspection. The site states that, in validation studies, the algorithms reached an area under the curve “near perfect” for both cancer detection and secondary features like Gleason patterns or perineural invasion. Thus, the intended user is a practicing pathologist or researcher who already has a digital pathology workstation and wants a second‑reader tool that can flag tiny foci of disease and provide quantitative grading.
In addition to the diagnostic algorithms, Ibex claims to have expanded its platform into early translational research and biomarker development, aiming to speed drug‑development pipelines. For this use case the software would process slide images from pre‑clinical studies, annotate biomarker‑positive areas, and generate reports to support biomarker discovery. The site does not describe any specific workflow or data‑export format for this research application, nor does it mention integration options with laboratory information systems.
The listed customers include large hospitals, diagnostic solution providers, and research institutions. The excerpts from pathologists describe increased confidence and reduced workload. However, the website provides no pricing model, no explicit list of supported slide scanner brands, nor details on how the software is installed or updated. No user guide or help center is linked, and there is no mention of data privacy compliance beyond a general GDPR note. The description also does not specify which operating systems the software runs on or whether a cloud or on‑premises deployment is required.
Key features
- Detects cancer and identifies over a hundred diagnostic attributes
Details
- Pricing
- Free
- Release date
- 2026-04-04
- Last checked
- 8h ago
- Indexing
- noindex, follow
- Category
- Writing
Suggest an edit
Sign in to suggest an edit.
Pros and cons
Pros
- Massive training set of more than 10 million slides
- Multiple clinically‑validated algorithms (breast, prostate)
- Near‑perfect agreement reported in validation studies
- Claimed to reduce workforce burden and improve diagnostic consistency
Cons
- Pricing information not disclosed
- No stated compatibility list for slide scanners or viewers
- Limited documentation on installation and integration
- Lacks explicit data‑privacy or compliance statements beyond GDPR reference

